TrialCancer medicine2019

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.

Nobuaki Sato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.